Aytu Biopharma, Inc (AYTU) Institutional Ownership

Ownership Summary

Recent 13F filings as of December 2025 show that 38 institutional investors hold a position in Aytu Biopharma, Inc (NASDAQ:AYTU).

• On a quarter-over-quarter basis, institutional holdings shifted by 5.85%, with a year-over-year an increase of 26.67% in the count of filers.
• During the quarter, 18 institutions bought more Aytu Biopharma shares, 6 sold shares, and 14 of the 38 total investors held their position steady.
• This class of investors increased its holdings in Aytu Biopharma to 3.77Mn shares for the 13F-cycle ending December 2025, up by 208.58K shares quarter on quarter, and up 1.89Mn shares year over year.
• As of December 31, 2025, Nantahala Capital Management, LLC held Aytu Biopharma's largest shareholding position with over 1.09Mn shares, representing 10.78% of total outstanding shares.
• Among the most significant buyers of Aytu Biopharma during December 2025 were TWO SIGMA INVESTMENTS, LP (38.40K), DIADEMA PARTNERS LP (33.12K), FNY Investment Advisers, LLC (31.47K), DRW Securities, LLC (29.37K), XTX Topco Ltd (25.86K).
• Leading sellers of Aytu Biopharma stock in December 2025 included Stonepine Capital Management, LLC (78.15K), RENAISSANCE TECHNOLOGIES LLC (5.50K), Tower Research Capital LLC (TRC) (2.61K), MORGAN STANLEY (161), UBS Group AG (86).
• The top 10 institutional holders of Aytu Biopharma for the quarter ending December 2025 included Nantahala Capital Management, LLC (1.09Mn), Stonepine Capital Management, LLC (813.70K), AWM Investment Company, Inc. (619.57K), DIADEMA PARTNERS LP (305.79K), VANGUARD GROUP INC (278.58K), TWO SIGMA INVESTMENTS, LP (107.13K), RENAISSANCE TECHNOLOGIES LLC (89.62K), Persistent Asset Partners Ltd (79.42K), GEODE CAPITAL MANAGEMENT, LLC (74.10K), TWO SIGMA ADVISERS, LP (42.50K).